NeuroPace Q3 2023 Earnings Report $13.77 -0.46 (-3.23%) As of 02/21/2025 04:00 PM Eastern Earnings HistoryForecast NeuroPace EPS ResultsActual EPS-$0.28Consensus EPS -$0.39Beat/MissBeat by +$0.11One Year Ago EPSN/ANeuroPace Revenue ResultsActual Revenue$16.43 millionExpected Revenue$14.23 millionBeat/MissBeat by +$2.20 millionYoY Revenue GrowthN/ANeuroPace Announcement DetailsQuarterQ3 2023Date11/6/2023TimeN/ANPCE Upcoming EarningsNeuroPace will be holding an earnings conference call on Tuesday, March 4 at 4:30 PM Eastern. Interested parties can register for or listen to the call. Conference Call ResourcesPress ReleaseNPCE Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by NeuroPace Earnings HeadlinesNeuroPace Completes Repurchase of 5.3 Million Shares of Its Common Stock from KCK Ltd.February 20 at 4:05 PM | globenewswire.comNeuroPace (NASDAQ:NPCE) Announces Equity Offering and Stock Repurchase PlanFebruary 20 at 2:03 AM | americanbankingnews.comCollect $7k per month from Tesla’s SECRET dividendThere's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a traditional dividend, there's a way to collect up to $7,013 per month from Tesla… starting as early as next month. This backdoor strategy is changing the game for smart investors. Want to see how it works?February 22, 2025 | Investors Alley (Ad)NeuroPace to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025February 19 at 4:05 PM | globenewswire.comNeuroPace Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional SharesFebruary 18, 2025 | markets.businessinsider.comNeuroPace Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional SharesFebruary 18, 2025 | globenewswire.comSee More NeuroPace Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like NeuroPace? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NeuroPace and other key companies, straight to your email. Email Address About NeuroPaceNeuroPace (NASDAQ:NPCE) operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.View NeuroPace ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles The Trade Desk Crashes on Earnings, But Growth Catalysts PersistHims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before EarningsAirbnb's Earnings: Sky High Results, Grounded Guidance?Is Coinbase Stock a Buy After Earnings?CVS Health: Earnings Beat Ignites Stock RallyQualcomm’s Post-Earnings Dip: A Prime Buying Opportunity? Upcoming Earnings Workday (2/24/2025)Intuit (2/25/2025)American Tower (2/25/2025)Bank of Montreal (2/25/2025)Bank of Nova Scotia (2/25/2025)Public Storage (2/25/2025)NVIDIA (2/26/2025)Synopsys (2/26/2025)Salesforce (2/26/2025)Lowe's Companies (2/26/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
